GlassScriptPhysician profile
Joel S Shavin
NPI 1255376075
$3,298.80
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,590 · 2020: $595 · 2021: $1,099 · 2022: $14.42.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,176.39 | 2019-2021 | |
| Janssen Biotech, INC. | $273.92 | 2019-2021 | |
| Ucb, INC. | $250.28 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $239.25 | 2019-2021 | |
| Genzyme Corporation | $185.70 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $159.96 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $137.79 | 2019-2021 | |
| Galderma Laboratories, L.P. | $136.24 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $92.65 | 2019-2021 | |
| Leo Pharma INC. | $75.96 | 2019-2021 | |
| Almirall LLC | $72.96 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2019 | |
| Pfizer INC. | $71.79 | 2019-2021 | |
| Biofrontera INC. | $68.80 | 2019-2021 | |
| Genentech USA, INC. | $57.20 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $34.49 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $25.88 | 2021 | |
| Dusa Pharmaceuticals, INC. | $24.22 | 2019 | |
| Lilly USA, LLC | $23.24 | 2019 | |
| Sun Pharmaceutical Industries INC. | $23.17 | 2019 | |
| Dermira, INC. | $22.34 | 2019 | |
| Mylan Pharmaceuticals INC. | $21.34 | 2019 | |
| Amgen INC. | $20.50 | 2019 | |
| Strata Skin Sciences, INC. | $19.56 | 2019 | |
| Kyowa Kirin, INC. | $13.17 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Shavin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.